Researchers from the University of Connecticut have worked in the development of a collection of propargyl-linked antifolate (PLA) chemotypes for infectious pathogens with different functionalities, including potential anti-cancer, anti-inflammatory and anti-infection activities.
Seismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.
Ventus Therapeutics US Inc. patents describe new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors potentially useful for the treatment of autoimmune disease, rheumatic diseases and liver diseases, among others.
Scientists from Recludix Pharma Inc. presented the preclinical characterization of REX-7117, an orally available, reversible, SH2 domain-targeting STAT3 inhibitor, being developed for the treatment of inflammatory diseases.
Kyverna Therapeutics Inc. has presented details on the development and preclinical characterization of KYV-102, an autologous fully human anti-CD19 CAR T-cell therapy developed for diseases driven by B cells, such as systemic lupus erythematosus (SLE), among others.
Our immune cells are not just “defenders” against deadly viruses and pathogens but also a great balancer for tissue homeostasis. For neurological disorders, understanding the neuro-immune axis could be key to treating previously untreatable conditions such as autism spectrum disorder, according to Jun R. Huh, professor of immunology at Harvard Medical School.
Researchers from EMD Serono Research and Development Institute Inc. hypothesized that modulation of two T-cell costimulatory pathways, such as CD28 and OX40, in one single molecule would be more efficient at controlling T-cell activation than modulating each pathway separately.
To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a CD19/CD70-targeting CAR therapy that is able to deplete activated alloreactive lymphocytes, while endowing dual targeting of CD19+ B cells and CD70+ T cells.
RSS
